Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease | Zendy

Tanya Simuni | Zendy; Brian Fiske | Zendy; Kalpana Merchant | Zendy; Christopher S. Coffey | Zendy; Elizabeth Klingner | Zendy; Chelsea CaspellGarcia | Zendy; David-Erick Lafontant | Zendy; Helen Matthews | Zendy; Richard Wyse | Zendy; Patrik Brundin | Zendy; David K. Simon | Zendy; Michael A. Schwarzschild | Zendy; David M. Weiner | Zendy; Charles S. Venuto | Zendy; Ted M. Dawson | Zendy; Liana Baker | Zendy; Melissa Kostrzebski | Zendy; Tina P. Ward | Zendy; Gary Rafaloff | Zendy; Parkinson Study Group NILO-PD Investigators and Collaborators | Zendy; Jamie Adams | Zendy; Erika Augustine | Zendy; Deborah Baker | Zendy; Alicia Brocht | Zendy; Cindy Casaceli | Zendy; Ken Eaton | Zendy; Sue Henderson | Zendy; Nichole McMullen | Zendy; Phounsavath Muneath | Zendy; Laura Trusso | Zendy; C. Field | Zendy; Saurav Brahmachari | Zendy; Liana S. Rosenthal | Zendy; Emily T. Carman | Zendy; Cornelia Kamp | Zendy; Patrick Bolger | Zendy; Claire Wegel | Zendy; Holly M. Reynolds | Zendy; Oren Levy | Zendy; Amber Servi | Zendy; Kelvin L. Chou | Zendy; Angela S Stovall | Zendy; Gian Pal | Zendy; Kellie Keith | Zendy; Kathryn A. Chung | Zendy; Joohi JimenezShahed | Zendy; Christine Hunter | Zendy; Binit Shah | Zendy; Katie Sullivan | Zendy; Albert Y. Hung | Zendy; Grace Bwala | Zendy; Meredith Spindler | Zendy; Alexandria Oliver | Zendy; Robert A. Hauser | Zendy; Claudia Rocha | Zendy; Eric Molho | Zendy; Sharon Evans | Zendy; Holly A. Shill | Zendy; Farah Ismail | Zendy; Natividad Stover | Zendy; Candace Cromer | Zendy; Courtney Blair | Zendy; L. Zhang | Zendy; Olga Kishchenko | Zendy; Matthew Swan | Zendy; Laura García Ramírez | Zendy; Samuel Frank | Zendy; Stephanie Burrows | Zendy; Andrew P. Duker | Zendy; Christina Gruenwald | Zendy; Karen Blindauer | Zendy; Lynn Wheeler | Zendy; Lauren Seeberger | Zendy; Abigail Simpson | Zendy; B.L. Scott | Zendy; Lisa Gauger | Zendy; Anwar Ahmed | Zendy; Yvette Pitchford | Zendy; Jennifer Mule | Zendy; Adolfo Ramirez–Zamora | Zendy; Derek B. Ridgeway | Zendy; John Slevin Slevin | Zendy; Renee Wagner Wagner | Zendy; Vanessa K. Hinson | Zendy; Shonna Jenkins | Zendy; John L. Goudreau | Zendy; Doozie Russell | Zendy; Zoltán Mari | Zendy; Lilliana Dumitrescu | Zendy; Jason Aldred | Zendy; Melissa Bixby | Zendy; Mark S. LeDoux | Zendy

AI Assistant Blog Pricing

Open Access

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease

Author(s) -

Tanya Simuni,

Brian Fiske,

Kalpana Merchant,

Christopher S. Coffey,

Elizabeth Klingner,

Chelsea CaspellGarcia,

David-Erick Lafontant,

Helen Matthews,

Richard Wyse,

Patrik Brundin,

David K. Simon,

Michael A. Schwarzschild,

David M. Weiner,

Jamie Adams,

Charles S. Venuto,

Ted M. Dawson,

Liana Baker,

Melissa Kostrzebski,

Tina P. Ward,

Gary Rafaloff,

Parkinson Study Group NILO-PD Investigators and Collaborators,

Jamie Adams,

Erika Augustine,

Deborah Baker,

Alicia Brocht,

Cindy Casaceli,

Ken Eaton,

Sue Henderson,

Nichole McMullen,

Phounsavath Muneath,

Laura Trusso,

C. Field,

Saurav Brahmachari,

Liana S. Rosenthal,

Emily T. Carman,

Cornelia Kamp,

Patrick Bolger,

Claire Wegel,

Holly M. Reynolds,

Oren Levy,

Amber Servi,

Kelvin L. Chou,

Angela S Stovall,

Gian Pal,

Kellie Keith,

Kathryn A. Chung,

Joohi JimenezShahed,

Christine Hunter,

Binit Shah,

Katie Sullivan,

Albert Y. Hung,

Grace Bwala,

Meredith Spindler,

Alexandria Oliver,

Robert A. Hauser,

Claudia Rocha,

Eric Molho,

Sharon Evans,

Holly A. Shill,

Farah Ismail,

Natividad Stover,

Candace Cromer,

Courtney Blair,

L. Zhang,

Olga Kishchenko,

Matthew Swan,

Laura García Ramírez,

Samuel Frank,

Stephanie Burrows,

Andrew P. Duker,

Christina Gruenwald,

Karen Blindauer,

Lynn Wheeler,

Lauren Seeberger,

Abigail Simpson,

B.L. Scott,

Lisa Gauger,

Anwar Ahmed,

Yvette Pitchford,

Jennifer Mule,

Adolfo Ramirez–Zamora,

Derek B. Ridgeway,

John Slevin Slevin,

Renee Wagner Wagner,

Vanessa K. Hinson,

Shonna Jenkins,

John L. Goudreau,

Doozie Russell,

Zoltán Mari,

Lilliana Dumitrescu,

Jason Aldred,

Melissa Bixby,

Mark S. LeDoux

Publication year - 2020

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2020.4725

Subject(s) - tolerability , medicine , placebo , clinical endpoint , nilotinib , parkinson's disease , randomized controlled trial , adverse effect , physical therapy , disease , pathology , alternative medicine , receptor , tyrosine kinase

There is a critical need for careful and independent validation of reported symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog